| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-8993(91)90970-7 |
| P698 | PubMed publication ID | 1909204 |
| P50 | author | Miles Herkenham | Q47816901 |
| P2093 | author name string | Herkenham M | |
| de Costa BR | |||
| Richfield EK | |||
| Lynn AB | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 267-274 | |
| P577 | publication date | 1991-05-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | |
| P478 | volume | 547 |
| Q51620133 | (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters |
| Q39236936 | 3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinoid CB1 and CB2 receptors. |
| Q38036236 | A brain on cannabinoids: the role of dopamine release in reward seeking |
| Q48150235 | A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain |
| Q42467326 | A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia |
| Q91379874 | Aberrant structural-functional coupling in adult cannabis users |
| Q73575705 | Activational role of cannabinoids on movement |
| Q59794350 | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
| Q43888192 | Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain |
| Q36636653 | Acute effects of THC on time perception in frequent and infrequent cannabis users |
| Q35035878 | Addictive potential of cannabinoids: the underlying neurobiology |
| Q47095297 | Addressing sufficiency of the CB1 receptor for endocannabinoid-mediated functions through conditional genetic rescue in forebrain GABAergic neurons |
| Q37387731 | Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area |
| Q40125857 | Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line |
| Q42517324 | Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. |
| Q36370445 | Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice |
| Q48477201 | Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice |
| Q37015433 | Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats |
| Q35626928 | Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2. |
| Q51447010 | Behavioral responses to a D1 dopamine agonist in weanling rats treated neonatally with cocaine and delta9-tetrahydrocannabinol. |
| Q44126671 | Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats |
| Q41035114 | Behavioural consequences of maternal exposure to natural cannabinoids in rats |
| Q43683747 | Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine. |
| Q90524726 | Brain activity of anandamide: a rewarding bliss? |
| Q35820005 | CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation |
| Q37648995 | CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations |
| Q34605794 | CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum |
| Q48569177 | Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. |
| Q48007584 | Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. |
| Q48407695 | Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry |
| Q42156155 | Cannabinoid Receptor-Regulated Cyclic AMP Accumulation in the Rat Striatum |
| Q49059668 | Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. |
| Q37760048 | Cannabinoid conditioned reward and aversion: behavioral and neural processes. |
| Q48435185 | Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease |
| Q48963650 | Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures |
| Q42469712 | Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol |
| Q48166054 | Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol |
| Q38935678 | Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells |
| Q34251331 | Cannabinoid receptor localization in brain: relationship to motor and reward systems |
| Q33984006 | Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis |
| Q34099012 | Cannabinoid receptors and the regulation of immune response |
| Q42451047 | Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain |
| Q36425951 | Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q48518726 | Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors |
| Q35294138 | Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors |
| Q38971616 | Cannabinoids and GI Disorders: Endogenous and Exogenous |
| Q35950914 | Cannabinoids and gene expression during brain development. |
| Q34520143 | Cannabinoids and neuroprotection |
| Q37599138 | Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells |
| Q28377147 | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata |
| Q44084440 | Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse |
| Q36892931 | Cannabis and endocannabinoid modulators: Therapeutic promises and challenges |
| Q48405803 | Cannabis and endogenous cannabinoid systems. |
| Q34699888 | Cannabis, the mind and society: the hash realities |
| Q45814311 | Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling. |
| Q34515581 | Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis |
| Q48389730 | Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats |
| Q42536101 | Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats |
| Q64814751 | Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats |
| Q46479983 | Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. |
| Q44530990 | Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats |
| Q43873792 | Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. |
| Q50622619 | College on problems of drug dependence meeting, Puerto Rico (June 1996) marijuana use and dependence. |
| Q48658239 | Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. |
| Q36453850 | Correlations between the Memory-Related Behavior and the Level of Oxidative Stress Biomarkers in the Mice Brain, Provoked by an Acute Administration of CB Receptor Ligands |
| Q26768644 | Current status of PET imaging in Huntington's disease |
| Q44687714 | Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors |
| Q42539438 | Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain |
| Q42277604 | Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists |
| Q42095959 | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism |
| Q36752224 | Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density |
| Q73101567 | Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain |
| Q44830723 | Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain |
| Q31900735 | Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse |
| Q48678685 | Differential treatment regimen-related effects of HU210 on CB(1) and D(2)-like receptor functionality in the rat basal ganglia. |
| Q52690256 | Disrupted striatal neuron inputs and outputs in Huntington's disease. |
| Q42473820 | Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity. |
| Q71601729 | Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments |
| Q73266799 | Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat |
| Q37734563 | Dopamine and glutamate in Huntington's disease: A balancing act. |
| Q22251247 | Dopamine release in the basal ganglia |
| Q35828317 | Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior |
| Q34273699 | Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate |
| Q48405857 | Drug-activation of brain reward pathways |
| Q41865699 | Effect of Acetaldehyde Intoxication and Withdrawal on NPY Expression: Focus on Endocannabinoidergic System Involvement |
| Q72567138 | Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice |
| Q42408299 | Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease. |
| Q48127886 | Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro |
| Q48696308 | Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions |
| Q42528679 | Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain |
| Q42528193 | Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain |
| Q44209138 | Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia |
| Q91594539 | Elevation of endocannabinoids in the brain by synthetic cannabinoid JWH-018: mechanism and effect on learning and memory |
| Q33350145 | Endocannabinoid Receptors: CNS Localization of the CB1 Cannabinoid Receptor |
| Q34003324 | Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward |
| Q35532072 | Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q39368845 | Endocannabinoid system in neurodegenerative disorders. |
| Q29042501 | Endocannabinoid-mediated synaptic plasticity and addiction-related behavior |
| Q33583792 | Endocannabinoids and striatal function: implications for addiction-related behaviours |
| Q35025270 | Endocannabinoids and their actions |
| Q33757950 | Endocannabinoids in the dentate gyrus |
| Q44723162 | Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. |
| Q33899850 | Endogenous cannabinoid signaling and psychomotor disorders |
| Q43064653 | Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine |
| Q35874137 | Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder |
| Q48726145 | Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices |
| Q44793025 | Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function |
| Q42520647 | Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. |
| Q55300833 | Expression and localization of CB1R, NAPE-PLD, and FAAH in the vervet monkey nucleus accumbens. |
| Q48136699 | Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide |
| Q34650334 | Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling |
| Q27317300 | Functional Connectivity Disruption in Neonates with Prenatal Marijuana Exposure |
| Q82029286 | Functional neurochemistry of the basal ganglia |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q43263219 | Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. |
| Q36452302 | Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. |
| Q34745063 | Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system |
| Q47242856 | Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. |
| Q36787826 | Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence |
| Q33751118 | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability |
| Q28203208 | Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets |
| Q36873051 | Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. |
| Q51035332 | Influence of three-day morphine-treatment upon impairment of memory consolidation induced by cannabinoid infused into the dorsal hippocampus in rats |
| Q48452719 | Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. |
| Q33996977 | Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels |
| Q33758351 | Interactions of Cannabinoids With Biochemical Substrates |
| Q37916772 | Intrinsic and integrative properties of substantia nigra pars reticulata neurons |
| Q35104780 | It could be habit forming: drugs of abuse and striatal synaptic plasticity. |
| Q42502109 | Lateral regions of the rodent striatum reveal elevated glutamate decarboxylase 1 mRNA expression in medium-sized projection neurons |
| Q33714838 | Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers |
| Q48406027 | Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus |
| Q31813503 | Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. |
| Q28755529 | Localization of CB1 cannabinoid receptor mRNA in the brain of the chick (Gallus domesticus) |
| Q51985298 | Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. |
| Q34699467 | Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats |
| Q73304376 | Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease |
| Q36861976 | Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. |
| Q42454808 | Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats. |
| Q45305400 | Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q73209550 | Median eminence nitric oxide signaling |
| Q33844393 | Methanandamide blocks amphetamine-induced behavioral sensitization in rats |
| Q35041427 | Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats |
| Q41371378 | Modulation of neurotransmission by cannabinoids in the basal ganglia |
| Q27014154 | Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction |
| Q34430714 | Modulation of transmitter release via presynaptic cannabinoid receptors |
| Q41191025 | Molecular neurobiology of the cannabinoid receptor. |
| Q48450601 | Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. |
| Q33720160 | Motor actions of cannabinoids in the basal ganglia output nuclei |
| Q34270199 | Multiple functions of endocannabinoid signaling in the brain. |
| Q45299472 | Nabilone increases choreatic movements in Huntington's disease |
| Q51080825 | Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. |
| Q35626920 | Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers |
| Q44451116 | Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia |
| Q34990029 | Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome |
| Q37132571 | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 |
| Q30834004 | Neuroimaging in Huntington's disease |
| Q35182054 | Neuroprotective strategies in Parkinson's disease : an update on progress |
| Q41809772 | Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. |
| Q28660631 | Novel song-stimulated dendritic spine formation and Arc/Arg3.1 expression in zebra finch auditory telencephalon are disrupted by cannabinoid agonism |
| Q47808605 | Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. |
| Q27004306 | Opioid receptor heteromers in analgesia |
| Q28268838 | Pathology of idiopathic dystonia: findings from genetic animal models |
| Q48881103 | Perinatal delta 9-tetrahydrocannabinol exposure in rats modifies the responsiveness of midbrain dopaminergic neurons in adulthood to a variety of challenges with dopaminergic drugs |
| Q42474019 | Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats. |
| Q34442847 | Pharmacology of cannabinoid CB1 and CB2 receptors. |
| Q43971441 | Postsynaptic endocannabinoid release is critical to long-term depression in the striatum |
| Q61814918 | Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products |
| Q43119533 | Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo. |
| Q42440191 | Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q34113369 | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia |
| Q42450816 | Region-specific impairments in striatal synaptic transmission and impaired instrumental learning in a mouse model of Angelman syndrome |
| Q56504097 | Regulation of DARPP-32 phosphorylation by Δ9-tetrahydrocannabinol |
| Q35046370 | Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist |
| Q44653991 | Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra |
| Q48124141 | Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants |
| Q33720167 | Role of endocannabinoids in brain development |
| Q36030335 | Role of systemic endocannabinoid CB-1 receptor antagonism in the acquisition and expression of fructose-conditioned flavor-flavor preferences in rats |
| Q44865127 | Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia |
| Q60155183 | Role of the superior colliculus in the motor effects of cannabinoids and dopamine |
| Q72120664 | Sex-dimorphic psychomotor activation after perinatal exposure to (-)-delta 9-tetrahydrocannabinol. An ontogenic study in Wistar rats |
| Q36972027 | Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems |
| Q36496045 | Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. |
| Q28571785 | Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids |
| Q37074591 | Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles |
| Q36508056 | Tardive dyskinesia and essential fatty acids |
| Q35014951 | Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. |
| Q52088305 | The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. |
| Q42445636 | The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats |
| Q38319183 | The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors |
| Q30404057 | The CB1 receptor as an important mediator of hedonic reward processing |
| Q42450193 | The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. |
| Q34988386 | The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. |
| Q43807460 | The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. |
| Q36083476 | The dopamine hypothesis of drug addiction: hypodopaminergic state. |
| Q28137626 | The effects of cannabinoids on the brain |
| Q37441554 | The effects of Δ9-tetrahydrocannabinol on the dopamine system. |
| Q37394164 | The endocannabinoid system as a target for the treatment of motor dysfunction |
| Q34587990 | The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome |
| Q100423040 | The endocannabinoid system in humans: significant associations between anandamide, brain function during reward feedback and a personality measure of reward dependence |
| Q34099000 | The endocannabinoid system: a physiological perspective on its role in psychomotor control |
| Q34786832 | The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. |
| Q28714675 | The evolution and comparative neurobiology of endocannabinoid signalling |
| Q29615356 | The molecular logic of endocannabinoid signalling |
| Q74106041 | The ratio of striatal D1 to muscarinic receptors changes in aging rats housed in an enriched environment |
| Q34268475 | The role of cannabinoids in neurodegenerative diseases |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q34974856 | The therapeutic potential of the cannabinoids in neuroprotection |
| Q33964721 | Therapeutic potential of cannabinoids in CNS disease |
| Q42507026 | Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. |
| Q37381132 | Trajectory of adolescent cannabis use on addiction vulnerability |
| Q44334367 | Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. |
| Q41173089 | Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae |
| Q42487505 | Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen |
| Q48415196 | Visual search in long-term cannabis users with early age of onset |
| Q34660703 | Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum |
| Q24680848 | [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor |
Search more.